iSERA Lifesciences Ltd (534920)
🎯 Key Takeaways
- Revenue declined 69.3% QoQ to ₹1 in Q1FY20.
- Market Cap
- ₹121
- P/B Ratio
- 250.72
- ROE
- -6.2%
- ROCE
- 2.5%
- Debt/Equity
- 22.05
- Promoter
- 58.6%
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 |
|---|---|---|---|---|
| Revenue | 10 | 4 | 4 | 1 |
| Operating Profit | 0 | 0 | 0 | -0 |
| OPM % | 0.7% | 1.9% | 3.3% | -0.9% |
| Net Profit | 0 | -0 | -0 | -0 |
| EPS | ₹0.02 | ₹-0.01 | ₹-0.03 | ₹-0.06 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 |
| Reserves | 3 | 4 | -10 | -10 |
| Borrowings | 6 | 2 | 10 | 11 |
| Total Liabilities | 25 | 25 | 20 | 18 |
| Fixed Assets | 3 | 4 | 1 | 1 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 25 | 25 | 20 | 18 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2019 |
|---|---|
| Operating | -0 |
| Investing | -0 |
| Financing | +1 |
| Net Cash Flow | +0 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 3.6% | 58.6% | 58.6% |
| FII | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% |
| Public | 91.1% | 35.7% | 35.4% |
| # Shareholders | 1,034 | 1,029 | 1,014 |
⚖️ Peer Comparison — IT - Software
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| TCS | 7.42 L Cr | 14.9 | 63.2% | — | 0.00 |
| INFY | 4.04 L Cr | 13.4 | 44.9% | — | 0.00 |
| HCLTECH | 3.34 L Cr | 19.1 | 31.6% | — | 0.00 |
| WIPRO | 1.57 L Cr | 12.6 | 18.1% | — | 0.19 |
| TECHM | 1.50 L Cr | 26.5 | 24.8% | — | 0.00 |
| LTM | 1.19 L Cr | 22.8 | 30.5% | — | 0.00 |
| OFSS | 93,676 | 27.4 | 60.3% | — | 0.00 |
| PERSISTENT | 83,371 | 42.9 | 32.7% | — | 0.00 |
| COFORGE | 77,559 | 35.6 | 25.6% | — | 0.04 |
| MPHASIS | 41,208 | 21.5 | 22.3% | — | 0.17 |
🔗 Peer Stock Analyses
📋 Recent Filings
- 🔴 Corporate Action2026-10-01iSERA Lifesciences announced the allotment of 1,61,82,800 equity shares at Rs 48.20 per share via share swap to shareholders of iSERA Biological Limit…
- 🟡 Board Meeting2026-10-01The board approved the allotment of 1,61,82,800 equity shares at Rs 48.20 per share via share swap to promoters and non-promoter investors, increasing…
- 🟡 Board Meeting2026-09-29iSERA Lifesciences held its 34th Annual General Meeting on 29 September 2026 via video conference, with 47 shareholders attending. The meeting covered…
- Announcement2026-09-28iSERA Lifesciences announced that its trading window will close on October 1, 2026, and remain closed until 48 hours after the release of un-audited f…
- 🔴 annual report2026-09-05The 34th Annual General Meeting of iSERA Lifesciences Limited (formerly Covidh Technologies Limited) is scheduled for September 29, 2026 via video con…
- 🟡 Board Meeting2026-09-05The 34th Annual General Meeting of iSERA Lifesciences Limited (formerly Covidh Technologies) is scheduled for September 29, 2026 at 3:00 PM IST via vi…
- 🟡 Board Meeting2026-09-01The board fixed September 29, 2026 as the date for the 34th Annual General Meeting to approve the audited standalone financial statements for FY2025-2…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day